49 results about "Interferon gamma" patented technology

The invention discloses an immunosensor for detecting cytokine interferon gamma through electrochemiluminescence as well as a preparation method and application of the immunosensor. The immunosensor comprises a three-electrode system consisting of an immunoelectrode, a reference electrode and a counter electrode, the immunoelectrode is a VMSF modified electrode confined to cerium dioxide nano enzyme and platinum nano particles, and is obtained by covalently immobilizing an IFN-gamma antibody and closing a non-specific site; when the immunosensor is used for detection, a solution containing luminol is used as an electrolyte. The CeO2 and the PtNPs which are confined in the nano channel show a remarkable synergistic catalysis effect. Compared with direct modification on a plate electrode, CeO2-PtNPs has higher catalytic activity and stability. The sensor provided by the invention is used for INF-gamma detection, has the advantages of high sensitivity, low detection limit and wide detection range, does not need complex pretreatment and separation processes during detection, reduces the detection cost, is simple to operate, and is suitable for large-scale application.

The invention discloses an effect of an Intestinia butyriproducens bacterium in anti-tumor immunotherapy, and finds that colonization of the Intestinia butyriproducens bacterium in intestinal tracts can inhibit growth of CT26 mouse subcutaneous transplanted tumors with poor response to the tumor immunotherapy, meanwhile, growth of human colorectal cancer cells is remarkably inhibited, and apoptosis of tumor cells is promoted for the first time. The application of the Intestinia butyriproducens bacterium in the anti-tumor immunotherapy has the advantages that the effect of the intestinia butyriproducens bacterium in the anti-tumor immunotherapy is achieved, and the application of the intestinia butyriproducens bacterium in the anti-tumor immunotherapy in the anti-tumor immunotherapy in the anti-tumor immunotherapy in the anti-tumor immunotherapy is achieved. Meanwhile, after colonization of the strain and combined administration of PD-1 monoclonal antibodies, the proportion of CD8 + T cells in mouse tumor infiltration lymphocytes is increased, the proportion of depleted PD-1 + CD8 + T cells is reduced, and the proportion of CD8 + T cells releasing functional cell factors interferon gamma and granzyme B is also increased, which shows that after colonization of the strain, the curative effect of tumor immunotherapy can be enhanced, and the tumor immunotherapy effect can be enhanced. The immunoregulation capability and the great clinical application value are realized.

The present invention discloses an enhanced tumor vaccine adjuvant, and specifically relates to the field of vaccine adjuvants, the adjuvant comprising granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-9 (IL-9), gamma interferon (IFN-γ) and at least one additional immunomodulatory factor, wherein the immunomodulatory factor is selected from tumor-specific antigen WT1, CD40 ligand (CD40L), Toll-like receptor agonist or a combination thereof. The tumor vaccine adjuvant of the present invention can enhance the body's immune response to the tumor vaccine and improve the prevention and treatment effect of the tumor vaccine on tumors.

An Interferon Gamma Inducible Protein 16 (IFI16) mutant gene and its use as a marker for predicting, diagnosing, or prognosticating risk or severity of chronic liver disease is described. As a result of performing genomic analysis on NAFLD and NASH patient groups, it was confirmed that the frequency of IFI16 single-nucleotide variants (SNVs) including rs2276404, rs73021847, rs7532207, and rs6940 was increased, and the expression of the IFI16 mutant gene was increased depending on the disease stage of liver disease. The IFI16 SNV was highly expressed in infiltrating macrophages, playing a role in macrophage-induced inflammatory processes, and the IFI16 variant bound more strongly to dsDNA than wild-type IFI16, exacerbating the impaired mitochondrial DNA-sensing response signaling of the IFI16-PYCARD-CASP1 pathway. Thus, the IFI16 mutant gene may be used for predicting, diagnosing, or prognosticating risk or severity of chronic liver disease.

The invention discloses an engineered exosome for breaking through a pyroptosis immune starting and maintaining barrier as well as a preparation method and application of the engineered exosome. The exosome is constructed by loading an immune checkpoint inhibitor into a pre-stimulated exosome, and the exosome is derived from immune cells, high-expression interferon gamma and granzyme A. The expression of the tumor cell GSDMB is up-regulated by delivering the interferon gamma through the exosome, and the exogenous granzyme A cuts the GSDMB to trigger pyroptosis; meanwhile, an immune checkpoint inhibitor blocks a PD-1 / PD-L1 pathway in situ, T cell depletion is reversed, and release of endogenous granzyme A is promoted; the pyroptosis cells release antigens to activate the T cells, the activated T cells continuously secrete granzyme A / interferon gamma to form a cascade amplification effect, and the problem of double barriers existing in the pyroptosis immune cycle of granzyme A-GSDMB is solved. The engineered exosome can improve the infiltration degree of CD8 + T cells, and is suitable for treating tumors such as liver cancer and non-small cell lung cancer.

The present disclosure relates to chimeric costimulatory receptors (CCR) specific to ICAM-1, e.g., the CCRs that comprise a 4-1BB (CD137) costimulatory domain and a ICAM-1 binding domain (e.g., a ICAM-1 -specific scFv). Composition comprising such CCRs and methods of using such CCRs for preventing and treating a cancer are also provided.

Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising interferon gamma.

Provided herein are novel constructs comprising gold nanoparticles bound to two types of cytokines, wherein the two types of cytokines comprise Tumor Necrosis Factor alpha (TNFα) and a cytokine selected from the group consisting of Interferon gamma (IFNγ) and Interleukin-12.

Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and / or a low or negative PD-L1 status are also provided.

The invention provides an anti-gamma interferon autoantibody positive prediction method and system based on machine learning, and relates to the technical field of machine learning. The method comprises the steps of data acquisition and preprocessing, feature coding and screening, model training and integration, probability output, risk classification and the like. Basic disease information, physical examination data and conventional laboratory indexes are fused to construct a standardized numerical value feature matrix, and a regularization screening and group sparse constraint mechanism is introduced to extract target features. A plurality of supervised machine learning models are adopted to construct a prediction system, and an individual AIGAs positive probability is output in combination with a cross validation and ensemble learning method. Finally, clinical decision is assisted through dynamic threshold setting and visual result display, high precision, high interpretability and good deployability are achieved, and a practical solution is provided for AIGAs intelligent screening in a resource limited scene.

Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and / or a low or negative PD-L1 status are also provided.

Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFNγ, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFNγ, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFNγ) signaling, including neutralizing anti-IFNγ antibodies.

A method for treating a subject having a diseased or atrophic state of fibrotic tissue, kidney disease and associated nerve endings, or for promoting tissue regeneration in muscle tissue is accomplished through exposing the tissue with a laser light having a wavelength of about 400 nm to about 700 nm, or more preferably having a wavelength of about 405 nm, about 532 nm, about 635 nm, or a combination thereof. Subsequent to exposure, mesenchymal stem cells can be administered to the subject. After the administration of mesenchymal stem cells, the tissue is further exposed to laser light having a wavelength of about 400 nm to about 700 nm, or a laser light having a single wavelength of about 400 nm to about 700 nm. The mesenchymal cells can be interferon gamma activated.

The invention relates to the technical field of cell biomedicine, in particular to umbilical cord mesenchymal stem cells with high PD-L1 expression, a culture method and application of the umbilical cord mesenchymal stem cells and a method for promoting PD-L1 expression through in-vitro energization. The umbilical cord mesenchymal stem cell in-vitro energizing inducer is based on a DMEM / F12 culture medium containing 3%-7% of human platelet lysis buffer, and further comprises the following components: a tumor necrosis factor alpha, interferon gamma, human serum albumin, transferrin, insulin, riboflavin, N-acetylcysteine and a vascular endothelial growth factor. The in-vitro energizing inducer reduces the content of a stimulating factor tumor necrosis factor alpha and interferon gamma, reduces immunogenicity abnormity caused by TNF-alpha, remarkably improves PDL1 expression and provides a basis for inflammation treatment. The influence of long-time stimulation on cell functions and activity is remarkably reduced through short-time factor-induced stimulation.

An induction method for a macrophage is provided, in which macrophages are cultured in the presence of exosomes produced from a mesenchymal stem cell to which interferon gamma has been added and are induced into anti-inflammatory macrophages. An anti-inflammatory macrophage-inducing agent includes exosomes produced from a mesenchymal stem cell to which interferon gamma has been added, as an active component. A pharmaceutical composition contains the inducing agent.

Methods of preparing mesenchymal stromal cells (MSCs) through co-stimulation with interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα), and methods for using the co-stimulated MSCs to treat conditions associated with exocrine glands. Co-treatment of MSCs with IFNγ and TNFα significantly enhances their trophic secretome, preserves their immunomodulatory capacity compared to untreated MSCs, and maximizes their therapeutic efficacy. The MSCs may be allogeneic to the recipient.

Provided is an anti-INF-γ antibody. Also provided are a composition comprising the antibody and a pharmaceutical application of the antibody in treating IFN-γ mediated syndrome.

The application discloses a DNA sulfur-modified bacillus subtilis and application thereof in alleviating alcoholic diseases, and relates to the field of biochemistry.The application provides a DNA sulfur-modified bacillus subtilis, which is named as Bacillus subtilis E10-1 and has a preservation number of CCTCC NO: M20253036.It is verified through animal experiments that the DNA sulfur-modified bacillus subtilis E10-1 is more resistant to alcohol than a strain in which sulfur modification is knocked out, can reduce the levels of indexes such as glutathione pyrotransaminase, glutathione transaminase and urea nitrogen in serum of a host after drinking alcohol, and the level of interferon gamma, can increase the levels of total protein, superoxide dismutase and glutathione peroxidase, can alleviate oxidative stress damage caused by alcohol, can reduce inflammatory reactions of various organ tissues, can maintain normal physiological functions of cells, can repair intestinal barriers, and can maintain intestinal flora homeostasis, so that alcoholic related diseases can be prevented and / or treated.

Chimeric interferon gamma (IFNG) receptors that include the extracellular domain of IFNG receptor 1 (IFNGR1) and / or IFNG receptor 2 (IFNGR2) fused to the intracellular domains of heterologous cytokine receptors are described. Upon activation of immune cells (such as T cells) expressing the chimeric receptors, the immune cells secrete IFN-g, which binds to the IFNG chimeric receptors and transmits signals that enhance the proliferation and / or function of the engineered immune cells. Such engineered immune cells can be used, for example, to enhance cancer immunotherapy.

A method of determining a likelihood of developing cancer therapy-related cardiac dysfunction (CTRCD) in a subject receiving an anthracycline and / or HER2 targeted therapy cancer treatment. Also disclosed herein is a method for treating a subject who is identified as being at risk of developing CTRCD. This disclosure also relates to a method of identifying if a subject with cancer to be treated with or an anthracycline and / or a HER2 targeted therapy treatment is likely to benefit from a cardioprotective treatment. Further disclosed is a panel or kit, the panel or kit comprising a plurality of detection agents specific for each of a set of biomarkers in a sample obtained from a subject with cancer, optionally selected from: angiopoietin-2 (ANGPT2), Endoglin (ENG), E-selectin, endothelin-1 (ET-1), myeloperoxidase (MPO), Interferon gamma-induced protein-10 (IP-10) and Interferon-α, and optionally a solid support.

The application relates to the technical field of stem cells, in particular to a mesenchymal stem cell culture system without heterogeneity and application thereof. The mesenchymal stem cell culture system without heterogeneity comprises a basic culture medium and an additive component, wherein the basic culture medium is DMEM / F12, and the additive component comprises: recombinant human transferrin, recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin, recombinant human interferon gamma, hydrocortisone, vitamin A, vitamin D2, vitamin B, human blood albumin, CTS KnockOut SR XenoFree, glutamine and dextran. The mesenchymal stem cell culture system without heterogeneity provided by the application improves the proliferation efficiency of primary culture and in-vitro expansion culture of mesenchymal stem cells, is high in safety, good in stability and suitable for large-scale popularization and application.

A chimeric antibody receptors with anti-cotinine antibodies linked, and uses thereof are disclosed. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.

The application discloses an egg white protein source peptide with the function of improving immunocompromise and application thereof, and belongs to the technical field of small molecule peptides. The egg white protein is subjected to enzymolysis by using a protease, and an albumin peptide is prepared by intercepting an enzymolysis product with a molecular weight less than 1000 Da, wherein the albumin peptide contains a tetrapeptide MSPF with the function of improving immunocompromise. Animal model function verification shows that the tetrapeptide MSPF and the albumin peptide containing the peptide segment can significantly improve immunocompromise, the number of macrophages is increased by 62.94%, the number of neutrophils is increased by 62.69%, and the content of interferon gamma is increased by 76.11%, thereby enhancing the immunity of the organism. The food-derived bioactive peptide has high biological safety. Therefore, the tetrapeptide MSPF or the albumin peptide containing the peptide segment can be applied to the preparation of medicines for improving immunocompromise or health care food for enhancing immunity, and has good market prospect and application potential.

The presently claimed and described technology provides methods for chemiluminescence-based assays for detecting interferon-gamma (IFN-γ) in a biological sample employing a dioxetane compound.

The present invention falls within the technical field of aquaculture, and specifically, the invention relates to a specific solution for preventing and treating bacterial diseases using a Lactococcus lactis lactic acid bacterium transformed to produce an interferon type II (IFN II) immunostimulating cytokine, particularly interferon gamma (IFNg or IFNγ). Said transformed bacterium has been deposited in the Chilean Microbial Genetic Resources Collection at INIA with accession number RGM 2416 dated 22 Oct. 2017. The invention is also related to an immunostimulating food for aquaculture species comprising the lactic acid bacterium transformed with IFN type II from salmonidae. Moreover, the invention relates to the method for preparing said probiotic food, the method for preparing said lactic acid bacterium expressing IFNg, in other words which produces a cytokine that stimulates the antibacterial immune response.

The invention discloses an egg white protein source peptide with an effect of improving immunocompromise and application of the egg white protein source peptide, and belongs to the technical field of small molecule peptides. Protease is used for carrying out enzymolysis on egg white protein, an enzymolysis product with the molecular weight smaller than 1000 Da is cut out to prepare albumin peptide, and the albumin peptide contains tetrapeptide MSPF with the effect of improving the immunocompromise. Animal model function verification shows that the tetrapeptide MSPF and the albumin peptide containing the peptide fragment can significantly improve low immune function, the number of macrophages is increased by 62.94%, the number of neutrophils is increased by 62.69%, and the content of interferon gamma is increased by 76.11%, so that the immunity of the organism is enhanced. The food-borne bioactive peptide is high in biological safety. Therefore, the tetrapeptide MSPF or the albumin peptide containing the peptide fragment can be applied to the preparation of medicines for improving immunocompromise or health-care foods for enhancing immunity, and has good market prospects and application potential.

Provided is an anti-INF-γ antibody. Also provided are a composition comprising the antibody and a pharmaceutical application of the antibody in treating IFN-γ mediated syndrome.

The present invention relates to the diagnosis and treatment of conditions in patients with elevated levels of CXCL9 and other biomarkers. Methods and compositions for the treatment of hemophagocytic lymphocytosis (HLH) are provided. The present disclosure also generally relates to methods and compositions for diagnosing and treating conditions associated with elevated levels of CXCL9, elevated levels of total IFN gamma, and other biomarkers. The present disclosure also relates to methods of treating, delaying the progression or otherwise ameliorating the symptom of a condition in a patient with elevated levels of CXCL9, elevated levels of total IFN gamma and other biomarkers using agents that intervene in or otherwise antagonize interferon gamma (IFN gamma) signaling, including neutralizing anti-IFN gamma antibodies.

The invention relates to new antigen binding molecules comprising (i) an antibody that specifically binds to a tumor associated antigen and (ii) an interferon gamma (IFNG) variant polypeptide that terminates with the C-terminal amino acid sequence KRKRP (SEQ ID NO:1), to the new IFNG variant polypeptides included therein, to methods of producing these molecules and to methods of using the same.

Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject. The disclosure is based, in part, on compositions comprising one or more compounds that promotes interferon, e.g., interferon gamma (IFNγ), response in the gut microbiome of a subject and / or enhance CDS T-cell activity in a subject and / or enhances the anti-tumor effects of certain immune checkpoint inhibitor ( ICI) therapies and chemotherapeutic agents. In some embodiments, the compositions are useful for treating a subject having cancer.